Variables | PCL-5 score | R square | R square change | F | P value | |||
B | β | T | P value | |||||
Step 1 | ||||||||
Age | −0.064 | −0.081 | −1.762 | 0.079 | 0.023 | 0.023 | 5.576 | 0.004 |
Female vs male | 3.452 | 0.146 | 3.166 | 0.002 | ||||
Step 2 | ||||||||
Age | −0.100 | −0.127 | −2.719 | 0.007 | 0.080 | 0.058 | 8.381 | <0.001 |
Female vs male | 4.253 | 0.180 | 3.940 | 0.000 | ||||
Duration of disease <1 year vs 1–5 years | −4.339 | −0.103 | −2.243 | 0.025 | ||||
Duration of disease >5 years vs 1–5 years | 0.170 | 0.007 | 0.156 | 0.876 | ||||
PGA-VAS scores | 1.055 | 0.210 | 4.612 | <0.001 | ||||
Step 3 | ||||||||
Age | −0.088 | −0.112 | −2.491 | 0.013 | 0.159 | 0.079 | 11.260 | <0.001 |
Female vs male | 3.797 | 0.161 | 3.579 | <0.001 | ||||
Duration of disease <1 year vs 1–5 years | −3.847 | −0.091 | −2.061 | 0.040 | ||||
Duration of disease >5 years vs 1–5 years | 0.182 | 0.008 | 0.174 | 0.862 | ||||
PGA-VAS scores | 0.905 | 0.180 | 4.014 | <0.001 | ||||
Q1: How dangerous is COVID-19 to life and health? | 0.457 | 0.047 | 0.964 | 0.336 | ||||
Q2: How much does COVID-19 affect life, work or study? | 1.816 | 0.175 | 3.544 | <0.001 | ||||
Q3: How confident are you in defeating COVID-19? | −3.086 | −0.217 | −4.970 | <0.001 | ||||
Step 4 | ||||||||
Age | −0.121 | −0.155 | −3.412 | 0.001 | 0.217 | 0.058 | 10.899 | <0.001 |
Female vs male | 3.471 | 0.147 | 3.323 | 0.001 | ||||
Duration of disease <1 year vs 1–5 years | −2.351 | −0.056 | −1.286 | 0.199 | ||||
Duration of disease >5 years vs 1–5 years | 0.556 | 0.024 | 0.546 | 0.586 | ||||
PGA-VAS scores | 0.561 | 0.112 | 2.473 | 0.014 | ||||
Q1: How dangerous is COVID-19 to life and health? | 0.520 | 0.053 | 1.130 | 0.259 | ||||
Q2: How much does COVID-19 affect life, work or study? | 1.331 | 0.128 | 2.642 | 0.009 | ||||
Q3: How confident are you in defeating COVID-19? | −2.754 | −0.194 | −4.545 | <0.001 | ||||
Subjective sleep quality | 1.627 | 0.110 | 1.999 | 0.046 | ||||
Difficulty falling asleep | 0.954 | 0.090 | 1.678 | 0.094 | ||||
Frequent nocturnal or early morning awakening | 0.715 | 0.072 | 1.401 | 0.162 | ||||
Sleep duration | 0.878 | 0.065 | 1.371 | 0.171 |
The duration of disease was transformed into two dummy variables (<1 year vs 1–5 years, >5 years vs 1–5 years), with 1–5 years as the reference group.
B, unstandardised beta; PCL-5, PTSD Checklist for DSM-5; PGA-VAS, Patient Global Assessment Visual Analogue Scale; RD, rheumatic disease; β, standardised regression weight.